Fig. 5

Propofol inhibits the expression of Rab5a and TLR4 on LPS-treated peripheral blood monocytes. peripheral blood monocytes from healthy volunteers were treated with LPS treated with LPS (1 μg/ml) for the indicated time with or without pretreatment of propofol (50 μM) for 30 min. A Membrane TLR4 expression of peripheral blood monocytes from healthy volunteers was analyzed by flow cytometry. CD14 antibody was used to mark monocytes. B Western blotting of Rab5a in peripheral blood monocytes from healthy volunteers. C Proinflammatory factor mRNA levels in peripheral blood monocytes from healthy volunteers were measured by qPCR. D Western blotting of Rab5a in peripheral blood monocytes from healthy volunteers and sepsis patients. N1 to N4 represent healthy volunteers and S1 to S4 represent sepsis patients. E Membrane TLR4 expression of peripheral blood monocytes from healthy volunteers and sepsis patients were measured by flow cytometry. Peripheral blood monocytes from sepsis patients were treated with propofol (50 μM) for 3 h. F Proinflammatory factor mRNA levels in peripheral blood monocytes from healthy volunteers and sepsis patients were measured by qPCR. Peripheral blood monocytes from sepsis patients were treated with propofol (50 μM) for 3 h. Data are expressed as the mean ± SD, n = 3–5, *p < 0.05, **p < 0.01,***p < 0.001, 1-way ANOVA with Tukey’s post hoc test. PPF propofol